Právní předpis byl sestaven k datu 01.02.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx I - Xxxxxx zakázaných látek x metod dopingu xxx xxx 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.
X xxxxx zněním Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Přílohy X Českou republikou.
Nové xxxxx Přílohy I xxxxxxxxx x platnost x xxxxxxx s článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Přílohu X pro rok 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X xxx rok 2024 x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x z. XXXx. Xxxxxx, Ph.D., LL.M., x. x.
xxxxxx xxxxxxx xxxxx právní a xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Překlad xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx
Xxxx
Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx standard x xxxxx Světového antidopingového xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx od 1. xxxxx 2024.
Oficiální xxxx Xxxxxxx zakázaných xxxxx x xxxxx bude xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x francouzským xxxxxx xxxxxxxxx znění x xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx látek x xxxxx.
Xxxxxxxx Při xxxxxxx
Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Sportovec xxxxxxxxx, xx xx konce Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx stále
To xxxxxxx, xx xxxx xxxxx xxxx metoda xx xxxxxxxx Xxx xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx x Kodexu.
Specifické x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „pro účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx x Seznamu xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx nebezpečné xxx xxxx dopingové xxxxx nebo metody. Xxx spíše o xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx látky
Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx jako látky, xxxxx jsou jako xxxxxx xxxxxxxx z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Návykové látky xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx látky.
Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx x následujících xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx nebo xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.
Tato xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx BPC-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x této třídě xxxx Nespecifické xxxxx.
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx xxxx včetně:
|
• |
1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
|
• |
1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) |
|
|
• |
1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol) |
• |
metyltestosteron |
|
|
• |
19-norandrostenedion (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-norpregna-4-en-17α-ol) |
• |
trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x další xxxxx x podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
S1.2. XXXXXXX XXXXXXXXXX LÁTKY
Mimo xxxx xxxxxx:
Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], xxxxxxx x xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x xxxxx látky x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX
Xxxx jiné xxxxxx:
X2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx a xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.
S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; daprodustat (XXX1278863); XXX2; molidustat (BAY 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xenon.
S2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx opravného receptoru, xxxx. asialo XXX; xxxxxxxxxxxxx EPO (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX
X2.2.1 Xxxxxxx stimulující testosteron x xxxx, xxxx xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• luteinizační xxxxxx (LH),
• xxxxxx xxxxxxxxxx gonadotropin (GnRH, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.
X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx xxxxxx (XX), xxxx analogy x fragmenty, mimo xxxx včetně:
• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. AOD-9604 x hGH 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) a xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5 x XXXX-6].
X2.3. XXXXXXX XXXXXXX X MODULÁTORY RŮSTOVÝCH XXXXXXX
Xxxx xxxx včetně:
• xxxxxxxxxxxxx xxxxxxx faktory (XXX)
• xxxxxxxxxxxx růstový xxxxxx (XXX)
• růstový xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• thymosin-β4 x xxxx xxxxxxxx, xxxx. TB-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx včetně xxxxx xxxxxxxxx izomerů jsou xxxxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: maximálně 25 mikrogramů xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx než 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx dávky (xxxxxxxxx) xx do výše xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 a X4.2 xxxx Specifické xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 a X4.4 jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. XXXXXXXXXX AROMATÁZ
Mimo xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on) |
• |
formestan |
|
|
• |
4-androsten-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty receptoru xxxxxxxx IIB, xxxx.: |
- xxxxx xxxxxxxxx nebo xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (např. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, stamulumab) |
S4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 aktivátory AMP-aktivované xxxxxxxxxxxxx (AMPK), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011
X4.4.2 insuliny x xxxxxxxx xxxxxxxx
X4.4.3 meldonium
S4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Diuretika, xxxx např.:
acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx látky x xxxxxxxx chemickou strukturou xxxx podobnými biologickými xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x xxxxxxx oftalmologické xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, brinzolamid);
• xxxxxxx podání xxxxxxxxxxx x zubní anestezii.
POZNÁMKA
Nález xxxxxxxxxxx xxxxxxxx látky xx stanoveným xxxxxxxx xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx udělena na xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX METODY
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxxx v xxxx třídě xxxx Xxxxxxxxxxxx s xxxxxxxx xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx x xxxxxxxx xxxxxxxx plazmy nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.
X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx nebo xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx a modifikované xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx náhražky na xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x výjimkou doplňkového xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x krví nebo x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx nebo Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx odebraných při Xxxxxxxxx xxxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:
M3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo exprese xxxx xxxxxxxxxx mechanismem. Xx mimo xxxx xxxxxxxx technologie xxxxx xxxx, xxxxxxxxx xxxx x technologie přenosů xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x výjimkou látek xxxxxxxxx x S6.A, xxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, včetně všech xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx jiné xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon a xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky
VÝJIMKY
• klonidin;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx kožního, xxxxxxx, očního xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx optických xxxxxxx, xxxx. x- x l, jsou xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Specifické xxxxx. Xxxxxxxx látky x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx zakázané, např.
• x konopí (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx
• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx THC
VÝJIMKY
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx glukokortikoidy xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx podání (včetně xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního a xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx používají x rámci xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx x xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx U-rampa / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• podvodní xxxxxx (CMAS)* x xxxxxxxxxxxx volného potápění, xxxx xxxxxxxx x xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (XXX)
• xxxx (XXX)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx také Xxxx soutěž
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx č. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) x jeho x-xxxxxx: xx xxxxxxxx xxxxx xxx koncentraci x xxxx vyšší xxx 5 mikrogramů x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 ml.
3) xxxxxxx x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 ml.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.
5) xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx předpisu